(Q36161243)

12 August 2017

1 reference

title

Therapeutic perspectives of adipocytokines (English)

1 reference

12 August 2017

6

Mathias Fasshauer

1 reference

12 August 2017

5

Michael Stumvoll

1 reference

12 August 2017

1

Susan Kralisch

1 reference

12 August 2017

3

Matthias Bluher

1 reference

12 August 2017

4

Ralf Paschke

1 reference

12 August 2017

Johannes Klein

2

1 reference

PubMed ID

15952917

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

1 reference

12 August 2017

6

1 reference

12 August 2017

6

1 reference

12 August 2017

863-872

1 reference

Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

AdipoQ is a novel adipose-specific gene dysregulated in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Disruption of adiponectin causes insulin resistance and neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adiponectin acts in the brain to decrease body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Expression of adiponectin receptors in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Growth hormone is a positive regulator of adiponectin receptor 2 in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Leptin: a novel therapeutic role in lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Regulation of adipocytokines and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Dose-dependent effects of recombinant human interleukin-6 on glucose regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Interleukin-6 induces cellular insulin resistance in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor- and Jak/Stat-signaling pathways in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

The therapeutic potential of interleukin-6 in treating obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Interleukin-6 protects MIN6 beta cells from cytokine-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Interleukin (IL)-6 mRNA Expression is Stimulated by Insulin, Isoproterenol, Tumour Necrosis Factor Alpha, Growth Hormone, and IL-6 in 3T3-L1 Adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Role of resistin in diet-induced hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Resistin gene expression in human adipocytes is not related to insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Regulation of fasted blood glucose by resistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.863

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/citations/10.1126/SCIENCE.1097243

Identifiers

DOI

10.1517/14656566.6.6.863

1 reference

12 August 2017

1 reference

PubMed ID

15952917